205 related articles for article (PubMed ID: 28694658)
21. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
[TBL] [Abstract][Full Text] [Related]
22. Conditional KCa3.1-transgene induction in murine skin produces pruritic eczematous dermatitis with severe epidermal hyperplasia and hyperkeratosis.
Lozano-Gerona J; Oliván-Viguera A; Delgado-Wicke P; Singh V; Brown BM; Tapia-Casellas E; Pueyo E; Valero MS; Garcia-Otín ÁL; Giraldo P; Abarca-Lachen E; Surra JC; Osada J; Hamilton KL; Raychaudhuri SP; Marigil M; Juarranz Á; Wulff H; Miura H; Gilaberte Y; Köhler R
PLoS One; 2020; 15(3):e0222619. PubMed ID: 32150577
[TBL] [Abstract][Full Text] [Related]
23. Senicapoc: Repurposing a Drug to Target Microglia K
Staal RGW; Weinstein JR; Nattini M; Cajina M; Chandresana G; Möller T
Neurochem Res; 2017 Sep; 42(9):2639-2645. PubMed ID: 28364331
[TBL] [Abstract][Full Text] [Related]
24. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
[TBL] [Abstract][Full Text] [Related]
25. The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis.
Flores-Costa R; Alcaraz-Quiles J; Titos E; López-Vicario C; Casulleras M; Duran-Güell M; Rius B; Diaz A; Hall K; Shea C; Sarno R; Currie M; Masferrer JL; Clària J
Br J Pharmacol; 2018 Mar; 175(6):953-967. PubMed ID: 29281143
[TBL] [Abstract][Full Text] [Related]
26. The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Regulating the Visceral Adipose-Tissue Function.
Kim J; Lee H; Lim J; Oh J; Shin SS; Yoon M
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420164
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-29a Suppresses CD36 to Ameliorate High Fat Diet-Induced Steatohepatitis and Liver Fibrosis in Mice.
Lin HY; Wang FS; Yang YL; Huang YH
Cells; 2019 Oct; 8(10):. PubMed ID: 31652636
[TBL] [Abstract][Full Text] [Related]
28. Melatonin improves non-alcoholic fatty liver disease via MAPK-JNK/P38 signaling in high-fat-diet-induced obese mice.
Sun H; Wang X; Chen J; Song K; Gusdon AM; Li L; Bu L; Qu S
Lipids Health Dis; 2016 Nov; 15(1):202. PubMed ID: 27876064
[TBL] [Abstract][Full Text] [Related]
29. Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis.
Chen X; Li L; Liu X; Luo R; Liao G; Li L; Liu J; Cheng J; Lu Y; Chen Y
Life Sci; 2018 Jun; 203():291-304. PubMed ID: 29709653
[TBL] [Abstract][Full Text] [Related]
30. Decrease in fat de novo synthesis and chemokine ligand expression in non-alcoholic fatty liver disease caused by inhibition of mixed lineage kinase domain-like pseudokinase.
Saeed WK; Jun DW; Jang K; Oh JH; Chae YJ; Lee JS; Koh DH; Kang HT
J Gastroenterol Hepatol; 2019 Dec; 34(12):2206-2218. PubMed ID: 31132314
[TBL] [Abstract][Full Text] [Related]
31. MiR-146b attenuates high-fat diet-induced non-alcoholic steatohepatitis in mice.
Jiang W; Liu J; Dai Y; Zhou N; Ji C; Li X
J Gastroenterol Hepatol; 2015 May; 30(5):933-43. PubMed ID: 25559563
[TBL] [Abstract][Full Text] [Related]
32. Alleviative effect of ciliary neurotrophic factor analogue on high fat-induced hepatic steatosis is partially independent of the central regulation.
Cui MX; Yang LN; Wang XX; Wang L; Li RL; Han W; Wu YJ
Clin Exp Pharmacol Physiol; 2017 Mar; 44(3):395-402. PubMed ID: 27973757
[TBL] [Abstract][Full Text] [Related]
33. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
34. KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.
Brown BM; Pressley B; Wulff H
Curr Neuropharmacol; 2018; 16(5):618-626. PubMed ID: 28676010
[TBL] [Abstract][Full Text] [Related]
35. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
[TBL] [Abstract][Full Text] [Related]
36. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
Ataga KI; Reid M; Ballas SK; Yasin Z; Bigelow C; James LS; Smith WR; Galacteros F; Kutlar A; Hull JH; Stocker JW;
Br J Haematol; 2011 Apr; 153(1):92-104. PubMed ID: 21323872
[TBL] [Abstract][Full Text] [Related]
37. The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
Schumacher JD; Kong B; Pan Y; Zhan L; Sun R; Aa J; Rizzolo D; Richardson JR; Chen A; Goedken M; Aleksunes LM; Laskin DL; Guo GL
Toxicol Appl Pharmacol; 2017 Sep; 330():1-8. PubMed ID: 28673684
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice.
Zhang ZC; Liu Y; Xiao LL; Li SF; Jiang JH; Zhao Y; Qian SW; Tang QQ; Li X
J Hepatol; 2015 Dec; 63(6):1466-75. PubMed ID: 26272872
[TBL] [Abstract][Full Text] [Related]
39. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
[TBL] [Abstract][Full Text] [Related]
40. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress.
Li BH; He FP; Yang X; Chen YW; Fan JG
Transl Res; 2017 Feb; 180():103-117.e4. PubMed ID: 27639593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
